Glow-in-the-Dark dye could help surgeons spot hidden cancer
NCT ID NCT06819228
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-phase trial tests a fluorescent dye attached to the cancer drug panitumumab to help surgeons see head and neck cancer during surgery. 18 adults with head and neck squamous cell carcinoma will receive the dye before surgery, and a special camera will highlight cancer tissue. The goal is to find the best dose for imaging and to improve tumor removal.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Panitumumab-IRDye800 (a fluorescently labeled version of the drug panitumumab)
What this could lead to
If successful, this approach could help surgeons remove more cancer tissue during surgery and find the right drug dose for future treatments.
What could go wrong
This is a very early, small study (18 people) focused on imaging and dosing, not treatment effectiveness. The dye is investigational and may not improve outcomes.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HNSCC are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Vanderbilt University Medical Center
RECRUITINGNashville, Tennessee, 37232, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••